Sphere Bio unveils high-precision cell selection assay for biotherapeutic development
Sphere Bio has launched a groundbreaking multiplexed assay kit that streamlines single-cell selection workflows by simultaneously assessing antibody productivity and cell viability. This innovative solution works with the company’s next-generation Cyto-Mine Chroma platform, promising to accelerate biotherapeutic development through advanced picodroplet microfluidics technology.
Revolutionary multiplexing capabilities
The Cyto-Cellect Human IgG Kappa and Viability Assay Kit represents a significant advancement in single-cell analysis, enabling researchers to identify and isolate viable, high-producing clones in one automated workflow. This new capability addresses a critical inefficiency in traditional screening methods, where approximately five percent of selected high-producing clones are actually apoptotic—dead or dying cells that yield false positives in downstream development.
“Our new assay kit is a game-changer for single-cell workflows. By integrating viability assessment with antibody detection, we can ensure that only the healthiest, most productive cells are selected, significantly improving the efficiency and outcomes of our customers’ research,” said Dr. Xin Liu, Senior Product Manager for Assays and Applications at Sphere Bio.
Enhanced efficiency through picodroplet technology
The Cyto-Mine Chroma platform utilises fluorescence-based assays in picodroplets to select single cells based on multiple markers – secreted, surface, or intracellular. This technology enables unprecedented throughput while dramatically reducing costs compared to conventional methods.
Key benefits of the new system include:
• Simultaneous analysis of productivity and viability markers
• Workflow reduction from months to hours
• Significantly lower operational costs
• Built-in monoclonality assurance
Expanding multiplexed assay portfolio
The new assay kit marks the first in a planned series of multiplex assays designed for the Chroma platform, which was launched in January 2025.
“The Cyto-Cellect Human IgG Kappa and Viability Assay Kit leverages the advanced capabilities of Cyto-Mine Chroma to deliver unparalleled precision in single-cell analysis,” explained Dr. Maryam Ahmadi, Director of Science at Sphere Bio. “The new assay represents the first launch in our roadmap of multiplex assays compatible with Chroma, bringing advanced multiplexing capabilities to our customers through our expanding portfolio of cutting-edge tools and solutions to accelerate scientific discovery.”
Based in Cambridgeshire, UK, Sphere Bio has established a global presence with direct sales and support staff throughout Europe and the United States, along with distribution channels across the Asia-Pacific region.
The company specialises in picodroplet microfluidic platforms specifically designed for single-cell screening and isolation, maintaining cell viability throughout the process.
For more information, visit: https://spherebio.com/product/cyto-cellect-human-igg-kappa-viability-assay-kit
Digital issue: Please click here for more information
